These Analysts Increase Their Forecasts On AbbVie After Strong Q3 Results
AbbVie beats Q3 estimates, raises 2026 revenue and earnings outlook, while analysts lift price targets to as high as $338.
Share
Why It Matters
AbbVie did better than people expected this quarter. When a company beats expectations and raises its outlook, it can signal the business is running well.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.